Aprea Therapeutics Reports $3.3 Million Net Loss and Strengthens Financial Position with $46.5 Million Cash

Aprea Therapeutics, Inc. reported a net loss of $3.3 million for the first quarter of 2026, a decrease from the $3.9 million loss recorded in the same period of 2025. The company did not generate any grant revenue during this quarter, a significant drop from the $162,463 reported in the previous year. Total operating expenses for the quarter were approximately $3.4 million, down from $4.2 million in the prior year, primarily due to reduced research and development costs, which fell from $2.5 million to $1.6 million. This reduction was largely attributed to the voluntary pause of the ABOYA-119 clinical trial, which impacted expenses related to the ATRN-119 program.

In terms of financial position, Aprea Therapeutics reported cash and cash equivalents of $46.5 million as of March 31, 2026, a substantial increase from $14.6 million at the end of 2025. This increase was primarily driven by financing activities, which provided $34.6 million in net cash during the quarter, following private placements of common stock and pre-funded warrants. The company’s total assets rose to $47.6 million, compared to $15.9 million at the end of the previous fiscal year, reflecting a significant strengthening of its financial resources.

Operationally, Aprea is focused on advancing its clinical programs, particularly APR-1051 and ATRN-119. The company has initiated a dose escalation study for APR-1051, with preliminary results indicating potential efficacy in patients with specific cancer mutations. As of April 30, 2026, six patients in the ongoing study exhibited stable disease, and the company plans to expand enrollment to include more patients with uterine serous carcinoma and other relevant cancer types. Meanwhile, the ATRN-119 program is being evaluated for potential combination therapies, although the ABOYA-119 trial is being wound down as part of this strategic shift.

Looking ahead, Aprea Therapeutics anticipates that its existing cash reserves will be sufficient to fund operations into the first quarter of 2028. The company expects to continue incurring significant expenses as it progresses its clinical trials and seeks to develop additional product candidates. Aprea's management remains focused on securing additional financing to support its ongoing operations and development activities, emphasizing the need for continued capital to achieve its long-term objectives in the oncology market.